Steven Lo is recorded as Board Member and CEO at Vaxart, Inc. (VXRT). The newest filing on record that lists Steven Lo as Board Member and CEO at Vaxart, Inc. (VXRT) is dated April 10, 2025. Vaxart, Inc. reported in an 8-K filed June 13, 2024 that Steven Lo was appointed Director, effective June 11, 2024. Vaxart, Inc. reported in an 8-K filed March 6, 2024 that Steven Lo was appointed member of the Board, effective March 18, 2024. Vaxart, Inc. reported in an 8-K filed March 6, 2024 that Steven Lo was appointed President, effective March 18, 2024. Equibles holds 4 filed executive changes naming Steven Lo; each is listed under recent activity with its source filing. The proxy statement of Vaxart, Inc. reports total compensation of $2,085,768 for Steven Lo in fiscal 2024, including a base salary of $473,810. Disclosed compensation is on record for 2 fiscal years. Steven Lo has spoken on 7 earnings calls across 1 company, most recently for Vaxart, Inc. on November 13, 2025. Vaxart, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Vaxart, Inc. includes Andrei Floroiu (CEO), Michael Finney (CEO), Michael J. Finney (CEO and Board Member) and 7 others.
“Stockholders elected the six nominees for directors to serve until the Company's 2025 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified.”
Vaxart, Inc. Form 8-K, filed June 13, 2024
· Read the filing
“On March 4, 2024, the Board of Directors (the "Board") of Vaxart, Inc. (the "Company") appointed Steven Lo as the Company's Chief Executive Officer, President, and principal executive officer, as well as a member of the Board, in each case effective as of March 18, 2024 (the "Start Date").”
Vaxart, Inc. Form 8-K, filed March 6, 2024
· Read the filing
Steven Lo on recent calls
“I'll begin today's call with an overview of our business, then we'll pass the call to James and Sean for the latest program developments. Jeroen will then share an update of our financials.”
“I'll begin today's call with an overview of our business. Then, we'll pass the call to James and Sean for the latest developments of our clinical and preclinical programs.”
“I'd like to begin today's call by acknowledging our partners at BARDA and the Department of Health and Human Services and thanking them for engaging with us in the productive dialogue that has led to the lifting of the stop work order on the 10,000 participant portion of our Project NextGen Phase 2b COVID-19 vaccine…”
“On today's call, I will highlight our business progress. I'll then have James and Sean share updates on our clinical and preclinical programs. Then, Phil will discuss our financial results before we open the call for your questions.”
“On today's call, I'm excited to highlight a number of accomplishments that we have achieved since our last update. I'll then have James and Sean share updates on our COVID, Norovirus and HPV programs respectively.”
